Pharmaceutical TechnologyOriginal article
FDA grants breakthrough therapy designation to Lilly’s olomorasib
RegulatoryolomorasibPositive
AI Analysis
Summary
The FDA has granted breakthrough therapy designation to Lilly's olomorasib for advanced pancreatic cancer in patients with prior systemic therapy exposure, accelerating its development pathway.
Outcome Details
FDA granted breakthrough therapy designation
Importance:7/10
Sentiment:
0.80
FDABreakthrough Therapy DesignationPancreatic CancerOncology
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 4, 2026 9:19 AM